Abstract Neurodevelopmental outcomes after the Norwood procedure for single right ventricular lesions are worse than those in the normal population. It would be valuable to identify which patients at the time of Norwood discharge are at greatest risk for neurodevelopmental impairment later in childhood. As such, this study sought to construct and validate a model to predict poor neurodevelopmental outcome using variables readily available to the clinician. Using data from the 14 month neurodevelopmental outcome of the Single-Ventricle Reconstruction (SVR) trial, a classification and regression tree (CART) analysis model was developed to predict severe neurodevelopmental impairment, defined as a Psychomotor Development Index (PDI) score lower than 70 on the Bayley Scales of Infant Development-II. The model then was validated using data from subjects enrolled in the Infant Single Ventricle (ISV) trial. The PDI scores were lower than 70 for 138 (44 %) of 313 subjects. Predictors of a PDI lower than 70 were post-Norwood intensive care unit
(ICU) stay longer than 46 days, genetic syndrome or other anomalies, birth weight less than 2.7 kg, additional cardiac surgical procedures, and use of five or more medications at hospital discharge. Using these risk factors, the CART model correctly identified 75 % of SVR subjects with a PDI lower than 70. When the CART model was applied to 70 subjects from the ISV trial, the correct classification rate was 67 %. This model of variables from the Norwood hospitalization can help to identify infants at risk for neurodevelopmental impairment. However, given the overall high prevalence of neurodevelopmental impairment and the fact that nearly one third of severely affected children would not have been identified by these risk factors, close surveillance and assessment for early intervention services are warranted for all infants after the Norwood procedure.
Keywords Congenital heart Á Neurodevelopment Á Outcomes Neurodevelopmental impairment constitutes a major morbidity among children and adolescents with complex congenital heart disease. Among this population, patients with hypoplastic left heart syndrome (HLHS) and other forms of single right ventricle are at greatest risk [15, 26] .
Previous studies have identified patient-and procedurerelated factors associated with neurodevelopmental deficits in children with HLHS who have undergone the Norwood procedure [5, 10, 12] . The ability to predict which children will have the most severe neurodevelopmental impairment could help to leverage early intervention strategies for patients faced by constraints of distance and financial resources. It also would be valuable for counseling parents.
Whereas traditional multivariable linear regression techniques have been useful in identifying risk factors, the mathematical formulas resulting from these analyses are not intuitive for busy clinicians to use. Ideally, it would preferable to construct a user-friendly predictive instrument for accurate classification of children into risk categories using variables readily available to the clinician.
The classification and regression tree (CART) is an analytic method that can identify high-and low-risk patient subgroups through a series of binary splits [3, 11] . As such, CART can simplify risk stratification. To develop a clinically useful risk stratification model of midterm neurodevelopment among patients after the Norwood procedure, the current study applied the CART analytic technique to a 14 month neurodevelopmental assessment of subjects enrolled in the Single Ventricle Reconstruction (SVR) trial carried out by the Pediatric Heart Network. The model then was validated using data from subjects enrolled in the Infant Single Ventricle (ISV) trial, also performed by Pediatric Heart Network investigators.
Methods

Subjects
The details of the SVR trial design have been published [22, 23] . Subjects were eligible for inclusion if they had a diagnosis of HLHS or a related single morphologic right ventricular anomaly and a planned Norwood procedure. The exclusion criteria ruled out any major congenital or acquired extracardiac abnormality that could independently influence transplant-free survival 12 months after randomization. The study protocol was approved by the institutional review board or research ethics board at each participating center, and written informed consent was obtained from a parent or guardian before randomization.
A validation of the model (described later) was undertaken using data from subjects who had single ventricle anomalies and had undergone the Norwood procedure as part of the Pediatric Heart Network Infant Single Ventricle (ISV) randomized trial of enalapril versus placebo examining a primary end point of somatic growth [9] .
This validation sample consisted only of subjects enrolled in the ISV trial but not enrolled in the SVR trial. The details of this trial have been published [8] . In brief, the inclusion criteria specified an age of 45 days or younger at enrollment, an age exceeding 1 week for patients born at 35 weeks gestation, presence of single-ventricle physiology, and planned superior cavopulmonary connection. The exclusion criteria ruled out an aortic oxygen saturation lower than 65 %, a creatinine level exceeding 1 mg/dl, an absolute neutrophil count lower than 1,000 cells/ml, and a chromosomal or recognizable phenotypic syndrome of noncardiac congenital abnormalities associated with growth failure.
Neurodevelopmental Assessment
The Bayley Scales of Infant Development-II Revised (BSID-II) allow a standardized assessment of cognitive and motor development for children 1-42 months of age [2] . The BSID-II yields summary scores for two domains: the Psychomotor Development Index (PDI) and the Mental Development Index (MDI). The mean PDI and MDI score in the normative population is 100 ± 15.
The BSID-II is an older instrument than the more recently released Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III). The BSID-II may be more sensitive than the BSID-III for identifying impairment in several high-risk groups, including the congenital heart disease population [1, 18] .
All the examiners completed protocol training and submitted a video showing administration of the instrument, which then was reviewed by a senior neuropsychologist. The BSID-II was administered in either English or Spanish depending on the dominant language spoken in the home. The results of this 14 month assessment have been presented previously [21] . The completion rate for the BSID-II examination among transplant-free survivors was 86 % (313/364). The mean age was 14.3 ± 1.1 months (range, 12.2-19.5 months).
Study Design and Measurements
In the SVR trial, subjects were randomly assigned to either a modified Blalock-Taussig shunt or a right ventricle-topulmonary artery shunt. In addition to genetics evaluations performed as part of routine clinical care, an optional research genetics evaluation was offered. The subjects were classified with regard to whether they had a specific genetic syndrome or other anomalies (i.e., not identified with a syndrome). The distribution of genetic syndromes in the SVR trial has been reported previously [25] .
For the current CART analysis, the primary outcome was the binary indicator of a PDI score lower than 70. Although the BSID-II yields both a PDI and a MDI scale, findings generally have shown the psychomotor domain to be more impaired in young children with congenital heart disease [4, 7] . As such, it would be expected that nearly all subjects with MDI scores lower than 70 also would have PDI scores lower than 70. The cutoff point of a score lower than 70, two standard deviations below the mean for the standard population, was chosen because this generally is recognized to represent severe impairment and would qualify a child for early intervention services in nearly all states [16, 19] .
Statistical Methods
Continuous variables are presented as mean ± standard deviation, and categorical variables are presented as counts and percentages. The CART analysis is a nonparametric technique that can identify from among a large number of variables and their interactions which are the most predictive of outcome. The CART method was used to generate a decision tree by a series of binary splits (recursive partitioning) of the data to predict the dichotomous variable PDI lower than 70 or 70 and higher. The CART model selects variables that provide the highest discriminatory power, and those that contribute the most to the outcome are listed first at the top of the tree.
Candidate predictors were demographic and clinical data available through the time of the Norwood procedure hospital discharge (Table 1) . Because variability in administration might influence BSID-II scores, we also examined a second decision tree that required the site to be included as a candidate predictor to adjust for potential differences in testing among centers. Receiver operating curves were constructed, and the area under the curve for the CART analysis is reported, with a higher value indicating better prediction.
The prediction rule arising from the CART analysis was validated using independent data from 70 subjects enrolled in the ISV trial. As with the SVR trial, ISV trial subjects underwent neurodevelopmental assessment at 14 months with the BSID-II. Analyses were performed using SAS version 9.2 (SAS Institute, Inc., Cary, NC, USA) and an open-source adaptation of the CART algorithm [24] .
Results
Development of the Model
The mean age at completion of the BSID-II was 14.3 ± 1.1 months. The cohort was 62 % male, had a weight z score of -0.7 ± 1.1 at BSID-II completion, was 20 % Hispanic, and had a 90 % proportion of patients with HLHS. The PDI scores were profoundly lower than those of the normative population. The scores were lower than 70 ([2 standard deviations below the expected mean) for 138 (44 %) of 313 subjects, significantly more than the expected frequency of 2 %.
The variables that remained in the discriminative CART model included the intensive care unit (ICU) stay longer than 46 days after the Norwood procedure, genetic or other anomalies, a birth weight lower than 2.7 kg, additional cardiac surgeries after the Norwood procedure during the hospital stay for the Norwood, and use of five or more medications at the time of Norwood hospitalization discharge (Fig. 1) . Notably, all the subjects with an ICU stay longer than 46 days had PDI scores lower than 70. None of the procedure-related variables such as shunt type, use of deep hypothermic circulatory arrest, or anatomic factors such as aortic atresia remained in the model.
The CART method correctly identified 75 % of the subjects (Tables 2, 3 ). Of the 138 subjects, 94 with a PDI lower than 70 were correctly classified (68 % sensitivity), and 140 of the 175 subjects with a PDI of 70 or higher were correctly classified (80 % specificity). Receiver operating characteristic curve analysis showed that the area under the curve (AUC) of the CART calculation was 0.78.
Because of the possibility that the testing site might influence BSID-II scores, we explored whether incorporation of 
Independent Validation Sample
The validation of the final CART model used data from 70 ISV trial subjects with single-ventricle anomalies who had undergone the Norwood procedure (Table 4) . Of the 70 subjects, 25 (36 %) had PDI scores lower than 70, which is not significantly different from the SVR trial rate of 44 % for PDI scores lower than 70 (p = 0.23). However, one predictive variable, the presence of a genetic syndrome or anomaly, was identified less frequently in the ISV cohort. Only 3 % of the ISV subjects were confirmed as having a genetic syndrome or a nonsyndromic anomaly compared with 25 % in the SVR trial (p \ 0.001).
The validation of the model using data from the ISV trial correctly predicted the classification for 67 % of the subjects. The classification was correct for 8 (32 %) of the 25 subjects with a PDI lower than 70 and for 39 (87 %) of the 45 subjects with a PDI of 70 or higher. Therefore, the model performed better in identifying infants who did not have severe impairment.
Discussion
Infants who undergo the Norwood procedure are at high risk for neurodevelopmental impairment as measured by the BSID-II administered just after the age of 12 months. Indeed, in the SVR trial, almost half of the subjects undergoing neurodevelopmental follow-up evaluation at the age of 14 months had PDI scores below 70, consistent with significant developmental impairment.
Many risk factors for adverse outcome such as the presence of genetic syndromes and other anomalies, low birth weight, and perioperative morbidity are manifest during the Norwood hospital stay. We thus hypothesized that CART analysis using clinical data available at the time of hospital discharge from the Norwood procedure would allow us to classify patients into high and low risk for severe neurodevelopmental impairment. Using the comprehensive database of the SVR trial, we found that the best model for predicting a PDI score lower than 70 correctly classified 75 % of the subjects evaluated at the age of 14 months but performed less well for our validation cohort from the ISV trial, correctly classifying 67 % of the patients.
The limited strength of the model may have several causes. Critical factors that predispose an infant with a single right ventricle to later developmental impairment may be hard to quantify or may not be routinely measured. For example, it is known that a proportion of these children may manifest preoperative brain injury on magnetic resonance imaging (MRI) even in the absence of acute clinical insults [13, 17] .
In addition, neurodevelopmental status at 14 months is influenced by many factors that occur beyond the initial Norwood hospital stay. Nearly all infants with HLHS undergo an additional cardiac surgery, the stage 2 procedure, in the first year life and may require additional unplanned interventions. As such, an infant with a relatively smooth Norwood hospital stay and no other overt risk factors in the neonatal period may have later exposures that increase the risk of neurodevelopmental impairment.
One particular limitation to the model in the ISV validation sample relates to the presence of genetic syndromes or other anomalies. Genetic abnormalities may affect both cardiac and brain development [6, 27] . The ISV study protocol excluded subjects with a chromosomal or recognizable phenotypic syndrome of noncardiac congenital abnormalities associated with growth failure. The more stringent exclusion criteria for some genetic syndromes in the ISV trial may in part account for the worse performance of the CART model in the validation sample. The relative importance of genetic syndromes and other anomalies for neurodevelopmental outcome underscores the need for a comprehensive genetic assessment in this population.
In spite of the aforementioned limitations, the CART analysis does provide some meaningful insights into factors that may influence neurodevelopmental outcome. It is known that a longer hospital stay has an association with subsequent developmental deficits [14, 20] . All subjects with an extended ICU stay ([46 days) after the Norwood procedure had PDI scores lower than 70. Birth weight less than 2.7 kg and the need for additional cardiac surgery during the Norwood hospital stay also were associated with later impairment. The number of medications prescribed to an infant at hospital discharge has not been explored previously as a predictor of later developmental status. However, this measure emerged as a risk factor that likely is a surrogate marker for overall health status. Its identification demonstrates the value of the agnostic approach to CART analysis.
Interestingly, intraoperative variables such as duration of deep hypothermic circulatory arrest or anatomic features such as aortic atresia did not contribute to risk stratification in the CART model. This finding is consistent with previous reports documenting that intraoperative variables explain only a small portion of variability in developmental outcomes [5, 7] .
In summary, comprehensive measurement of risk factors at the time of Norwood discharge for infants with HLHS and other single right ventricle anomalies correctly classifies 75 % of infants at risk for severe neurodevelopmental impairment. However, the best model would misclassify a considerable number of subjects as lower risk who at 14 months had PDI scores lower than 70. If referral for early intervention were limited on the basis of an early prediction model alone, such as the CART tree, these highrisk children might not receive appropriate services. Due to the high prevalence of neurodevelopmental impairment, close surveillance and early intervention services are warranted for all young children after the Norwood procedure. 
